New drug tested for Tough-to-Treat cancers
NCT ID NCT06238687
First seen Apr 16, 2026 · Last updated Apr 16, 2026
Summary
This study tested a new drug called STRO-002 in Chinese adults with advanced solid tumors, including ovarian and endometrial cancer, that had stopped responding to standard treatments. The main goals were to find a safe dose, see how the body processes the drug, and check for early signs that it might help shrink tumors. It involved 19 participants and was an early-stage trial to gather initial data.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASM MALIGNANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Conditions
Explore the condition pages connected to this study.